DI GIORGIO, CRISTINA
 Distribuzione geografica
Continente #
AS - Asia 1.112
NA - Nord America 1.105
EU - Europa 713
SA - Sud America 148
AF - Africa 33
OC - Oceania 4
Totale 3.115
Nazione #
US - Stati Uniti d'America 1.059
SG - Singapore 522
IT - Italia 212
CN - Cina 168
HK - Hong Kong 130
RU - Federazione Russa 116
BR - Brasile 108
IE - Irlanda 101
VN - Vietnam 98
DE - Germania 71
KR - Corea 51
FR - Francia 46
FI - Finlandia 28
CA - Canada 26
GB - Regno Unito 23
IN - India 20
NL - Olanda 19
BD - Bangladesh 18
IQ - Iraq 17
PL - Polonia 17
TR - Turchia 17
AT - Austria 16
MX - Messico 15
UA - Ucraina 13
JP - Giappone 12
SE - Svezia 12
AR - Argentina 11
PK - Pakistan 11
BE - Belgio 9
ZA - Sudafrica 9
CO - Colombia 8
ES - Italia 8
SA - Arabia Saudita 8
EC - Ecuador 7
ID - Indonesia 7
VE - Venezuela 6
MA - Marocco 5
AE - Emirati Arabi Uniti 4
CI - Costa d'Avorio 4
TN - Tunisia 4
BO - Bolivia 3
CH - Svizzera 3
IL - Israele 3
KW - Kuwait 3
PH - Filippine 3
AU - Australia 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
DZ - Algeria 2
GR - Grecia 2
KE - Kenya 2
KZ - Kazakistan 2
LB - Libano 2
MY - Malesia 2
NZ - Nuova Zelanda 2
OM - Oman 2
RO - Romania 2
SN - Senegal 2
SY - Repubblica araba siriana 2
UY - Uruguay 2
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
CL - Cile 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GP - Guadalupe 1
GT - Guatemala 1
HU - Ungheria 1
IM - Isola di Man 1
IR - Iran 1
LK - Sri Lanka 1
LT - Lituania 1
MK - Macedonia 1
MN - Mongolia 1
MU - Mauritius 1
NO - Norvegia 1
NP - Nepal 1
PE - Perù 1
PY - Paraguay 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TW - Taiwan 1
UZ - Uzbekistan 1
YT - Mayotte 1
Totale 3.115
Città #
Singapore 416
Chandler 133
Ashburn 131
San Jose 131
Hong Kong 130
Dublin 97
Perugia 95
Seoul 51
Santa Clara 46
Moscow 45
Boardman 41
Munich 39
Lauterbourg 34
Los Angeles 33
Beijing 31
Hanoi 22
Ho Chi Minh City 22
San Mateo 22
Dong Ket 21
New York 21
Piscataway 21
Ann Arbor 20
Medford 16
Princeton 16
Warsaw 16
Altamura 15
São Paulo 15
Lawrence 13
Brooklyn 12
Helsinki 12
Milan 12
Tokyo 12
Turku 12
Council Bluffs 11
The Dalles 11
Wilmington 11
Amsterdam 10
Hefei 10
Nuremberg 10
Brussels 9
Toronto 9
Baghdad 8
Dallas 8
Orem 8
Stockholm 8
Des Moines 7
Frankfurt am Main 7
Rome 7
Seattle 7
Vicenza 7
Vienna 7
Chicago 6
Denver 6
Houston 6
Mexico City 6
Montreal 6
Naples 6
Poplar 6
Redwood City 6
Chennai 5
Florence 5
San Francisco 5
Abidjan 4
Andover 4
Ankara 4
Bologna 4
Den Haag 4
Dubai 4
Johannesburg 4
Lahore 4
Lappeenranta 4
London 4
Querétaro 4
Riyadh 4
Saint Petersburg 4
Atlanta 3
Buffalo 3
Calgary 3
Can Tho 3
Columbus 3
Curitiba 3
Fortaleza 3
Haiphong 3
Jeddah 3
Karachi 3
Manchester 3
Miami 3
New Delhi 3
Quito 3
Redmond 3
Secaucus 3
Shanghai 3
Vancouver 3
Zhengzhou 3
As Sālimīyah 2
Athens 2
Belo Horizonte 2
Betim 2
Biên Hòa 2
Bogotá 2
Totale 2.092
Nome #
Increasing the Astrophysical Reach of the Advanced Virgo Detector via the Application of Squeezed Vacuum States of Light 137
The aryl hydrocarbon receptor (AhR) mediates the counter-regulatory effects of pelargonidins in models of inflammation and metabolic dysfunctions 116
Identification of Cysteinyl-leukotriene-receptor 1 antagonists as ligands for the bile acid receptor GPBAR1 112
Discovery of a AHR pelargonidin agonist that counter-regulates Ace2 expression and attenuates ACE2-SARS-CoV-2 interaction 109
Discovery of a Novel Multi-Strains Probiotic Formulation with Improved Efficacy toward Intestinal Inflammation 103
Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G-Protein Bile Acid Receptor 1/Farnesoid X Receptor Agonism and Statins in the Treatment of Nonalcoholic Fatty Liver Disease 101
Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling 100
The Bile Acid Receptor GPBAR1 Modulates CCL2/CCR2 Signaling at the Liver Sinusoidal/Macrophage Interface and Reverses Acetaminophen-Induced Liver Toxicity 99
Analysis of Oral and Gut Microbiota Composition in Children with Dental Caries by NGS Approaches 98
The bile acid activated receptors GPBAR1 and FXR exert antagonistic effects on autophagy 95
Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis 94
Bile Acids Activated Receptors in Inflammatory Bowel Disease 92
GLP-1 Mediates Regulation of Colonic ACE2 Expression by the Bile Acid Receptor GPBAR1 in Inflammation 91
Discovery of a Potent and Orally Active Dual GPBAR1/CysLT1R Modulator for the Treatment of Metabolic Fatty Liver Disease 91
Development of dual GPBAR1 agonist and RORγt inverse agonist for the treatment of inflammatory bowel diseases 85
GPBAR1 Functions as Gatekeeper for Liver NKT Cells and provides Counterregulatory Signals in Mouse Models of Immune-Mediated Hepatitis 85
GPBAR1 Activation by C6-Substituted Hyodeoxycholane Analogues Protect against Colitis 84
The leukemia inhibitory factor regulates fibroblast growth factor receptor 4 transcription in gastric cancer 83
Combinatorial targeting of GPBAR1 and CYSLTR1 reveals a mechanistic role for bile acids and leukotrienes in drug induced liver injury 82
Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH 79
Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma 79
Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling 78
Activation of GPBAR1 attenuates vascular inflammation and atherosclerosis in a mouse model of NAFLD-related cardiovascular disease 77
Repositioning Mifepristone as a Leukaemia Inhibitory Factor Receptor Antagonist for the Treatment of Pancreatic Adenocarcinoma 74
Allo-lithocholic acid, a microbiome derived secondary bile acid, attenuates liver fibrosis 73
Design, Synthesis, and Pharmacological Evaluation of Dual FXR-LIFR Modulators for the Treatment of Liver Fibrosis 72
Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders 72
Discovery of a Novel Class of Dual GPBAR1 Agonists-RORγt Inverse Agonists for the Treatment of IL-17-Mediated Disorders 67
Bile acids serve as endogenous antagonists of the Leukemia inhibitory factor (LIF) receptor in oncogenesis 66
Next-Generation Sequencing Analysis of Gastric Cancer Identifies the Leukemia Inhibitory Factor Receptor as a Driving Factor in Gastric Cancer Progression and as a Predictor of Poor Prognosis 66
Liver GPBAR1 Associates With Immune Dysfunction in Primary Sclerosing Cholangitis and Its Activation Attenuates Cholestasis in Abcb4−/− Mice 65
Immunology of bile acids regulated receptors 59
Organoids as ex vivo culture system to investigate infection-host interaction in gastric pre-carcinogenesis 54
Bile Acids-Based Therapies for Primary Sclerosing Cholangitis: Current Landscape and Future Developments 53
BAR502/fibrate conjugates: synthesis, biological evaluation and metabolic profile 51
Microbial-derived bile acid reverses inflammation in IBD via GPBAR1 agonism and RORγt inverse agonism 50
Modeling Inflammatory Bowel Disease by Intestinal Organoids 47
Current Landscape and Evolving Therapies for Primary Biliary Cholangitis 42
Leukemia inhibitory factor promotes human cholangiopathies, and its inhibition improves cholestasis in Abcb4 −/− mice 38
Harnessing the Estradienone Scaffold to Develop Dual GPBAR1 and LIFR Modulators for Liver Fibrosis 23
Tumor-Derived LIF Promotes GDF15-Driven Cachexia and Adverse Outcomes in Gastric Cancer 23
LIFR antagonism reverses epithelial pro-CAF programs in pancreatic ductal adenocarcinoma 18
A bile acid–GPBAR1 network supports anti-inflammatory and anti-fibrotic benefits of probiotics in colitis 18
Totale 3.201
Categoria #
all - tutte 13.838
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.838


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202132 0 0 0 0 0 0 0 0 0 6 4 22
2021/2022125 2 20 0 3 1 1 11 21 3 15 16 32
2022/2023409 27 61 3 35 38 46 0 22 151 2 14 10
2023/2024204 10 15 4 6 12 1 47 28 19 9 33 20
2024/2025771 9 57 39 52 46 74 50 79 158 35 113 59
2025/20261.589 108 110 90 240 248 138 252 86 168 149 0 0
Totale 3.201